225 related articles for article (PubMed ID: 32349720)
1. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis.
Koarai A; Sugiura H; Yamada M; Ichikawa T; Fujino N; Kawayama T; Ichinose M
BMC Pulm Med; 2020 Apr; 20(1):111. PubMed ID: 32349720
[TBL] [Abstract][Full Text] [Related]
2. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
3. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
4. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
5. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
[TBL] [Abstract][Full Text] [Related]
7. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis.
Koarai A; Yamada M; Ichikawa T; Fujino N; Kawayama T; Sugiura H
Respir Res; 2021 Jun; 22(1):183. PubMed ID: 34154582
[TBL] [Abstract][Full Text] [Related]
8. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335
[TBL] [Abstract][Full Text] [Related]
9. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
10. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
Oba Y; Chandran AV; Devasahayam JV
COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.
Schlueter M; Gonzalez-Rojas N; Baldwin M; Groenke L; Voss F; Reason T
Ther Adv Respir Dis; 2016 Apr; 10(2):89-104. PubMed ID: 26746383
[TBL] [Abstract][Full Text] [Related]
12. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis.
Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T
Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
Gong Y; Lv Y; Liu H; Zheng Q; Li L
Ther Adv Respir Dis; 2022; 16():17534666211066068. PubMed ID: 35001708
[TBL] [Abstract][Full Text] [Related]
14. Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials.
Chen WC; Huang CH; Sheu CC; Chong IW; Chu KA; Chen YC; Tsai JR; Lee CH; Wei YF
Respirology; 2017 Oct; 22(7):1313-1319. PubMed ID: 28654201
[TBL] [Abstract][Full Text] [Related]
15. Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.
Han MK; Ray R; Foo J; Morel C; Hahn B
NPJ Prim Care Respir Med; 2018 Aug; 28(1):32. PubMed ID: 30150639
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
[TBL] [Abstract][Full Text] [Related]
17. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW; Kim HJ; Jang EJ; Lee CH
Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
